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ABSTRACT 
Background and aims: Medication dosage adjustments for renally impaired patients have not been 
studied in Botswana. This study was conducted to determine prescribing practices among patients with 
renal impairment in medical wards to improve future patient care. Methods: We conducted a 
retrospective study involving medical charts of patients admitted at a tertiary level hospital in Gaborone 
Botswana. Study participants included all patients admitted between August and October 2016 who 
were hospitalized for ≥24 hours. “Drug prescribing in renal failure: dosing guidelines for adults and 
children.” was used to determine extent of dosage adjustments. A logistic regression model was used to 
assess which patient factors were associated with inappropriate dosage adjustment. Results: Twenty 
nine percent (233/804) of patients had renal impairment. Of these, 184 patients with renal impairment 
were included in the final analysis. There were 1143 prescription entries, of which 20.5% (n=234) 
required dosage adjustment for renal function but only 45.7% (n=107) were adjusted correctly. Of note, 
112 patients were prescribed at least one drug that required dosage adjustment and only 30.4% (n=34) 
patients had all of their medications appropriately adjusted. Patient factors associated with 
inappropriate dosage adjustment included a higher number of medicines being prescribed. Mortality 
among patients with renal impairment was independently associated with higher scores of Charlson 
comorbidity index and hospital stay duration of 1-7 days. Conclusion: The renal function status of 
patients was not sufficiently taken into account when prescribing medicines especially in patients with 
severely impaired kidney function in Botswana. Continuous medical education needs to be encouraged 
to address this, which is being implemented. We will be following this up in future studies. 
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1. INTRODUCTION 
 
Elimination of most medicines and their active metabolites is dependent on renal filtration, secretion and 
re-absorption [1]. In renal impairment, the clearance of medicines eliminated primarily by the kidney is 
decreased, and dosage adjustment should be considered when medicines are prescribed to patients with 
impaired renal function [2]. Over and above this, most medicines and their active metabolites have the 
potential to induce nephrotoxicity, or worsen renal impairment [3]. This is the case for instance for certain 
medicines for patients with human immune-deficiency virus (HIV), which is very prevalent in Botswana 
and across sub-Saharan Africa [4, 5]. For instance, at one stage, nearly 50% of the women in Botswana 
aged 30 to 34 years had HIV [5], and an appreciable proportion of hospitalized patients in Botswana are 
HIV positive [6]. HIV is itself an independent risk factor for kidney disease [7]. 
 
Studies have reported that 20-67% of prescriptions for patients with impaired renal function contain errors 
[8, 9]. There are many causes for these prescribing errors, which include prescribers’ poor knowledge of 
medications requiring dosage adjustment, the presence of renal impairment being overlooked by 
prescribers, underestimation of potential adverse events of medicines, and the lack of evidence-based 
data to guide prescribers on precautions and dosage adjustments [10, 11]. Drug-related problems can 
result in an increase in morbidity and mortality, as well as an increase in the cost of healthcare [12]. 
 
There is currently no data on the extent of application of any medication adjustment guidelines among 
renally impaired patients in Botswana. This is a concern especially among patients with HIV in Botswana. 
Consequently, this study was conducted to assess the patterns of medication dose adjustments among 
patients with renal impairment admitted to a tertiary hospital and its clinical outcomes in Botswana. As a 
result, provide guidance for the future care of these patients in this and other hospitals in Botswana as 
well as wider 
 
 
 
 
2. METHODOLOGY 
2.1 STUDY SITE 
Princess Marina Hospital (PMH) was chosen for this initial investigation as it is the leading tertiary hospital 
in Botswana training future physicians. It is also the leading hospital for treating patients with HIV in 
Botswana, and also treats ambulatory care patients from Gaborone and across the Southern part of 
Botswana with non-communicable diseases (NCDs) such as chronic kidney diseases, hypertension and 
diabetes [13]. There are two medical wards in the hospital, male and female medical wards, with bed 
capacities of 30 patients in each and a monthly admission rate ranging from 125-150 patients per ward. 
Consequently, if there are concerns with renally impaired patients in this setting, these are likely to be 
echoed throughout Botswana. A similar situation may also exist in other African countries with high rates 
of both HIV and NCDs such as diabetes [14-16].  
 
2.2 STUDY DESIGN AND POPULATION 
This was a descriptive retrospective cross-sectional study conducted during August to October 2016. All 
patients admitted to the male and female medical wards and aged 14 years and above were included in 
the study. The medical charts of eligible patients were reviewed for the level of creatinine at admission or 
during the course of inpatient treatment during the study period to understand their renal impairment 
status. Renal impairment constituted four groups of patients; - firstly those with documented chronic 
kidney disease with evidence of at least two elevated serum creatinine three months apart, secondly 
patients with end stage renal disease (ESRD) on renal replacement therapy in the form of haemodialysis 
or peritoneal dialysis. The third group consisted of patients admitted either without baseline serum 
creatinine or with some results of serum creatinine in the integrated patient management system (IPMS). 
Those patients without previous serum creatinine had their estimated baseline serum creatinine back-
calculated using the MDRD (Modification of Diet in Renal Disease) equation with an estimated GFR 
(glomerular filtration rate) of 75ml/min/1.73m2 in a similar way to previous studies [17]. Patients with 
previous several creatinine results had the minimum serum creatinine available within the past 12 months 
considered as baseline similar to a previous study [18]. For both categories in the third group, obtained 
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values were compared to values of serum creatinine at admission to establish whether these patients had 
evidence of renal impairment according to KIDGO criteria for AKI [19]. The fourth group comprised 
patients who were admitted with serum creatinine within the normal laboratory hospital range but 
developed renal impairment over the course of hospital admission. 
 
Exclusion criteria included admission of less than 24 hours either due to discharge or death, patients 
admitted for a day procedure such as gastroscopy, and patients whose renal function tests were either 
not undertaken or not traceable.  
 
 
2.3 SAMPLE SIZE CALCULATION AND TOTAL NUMBER OF PATIENTS 
Based on the prevalence of inappropriate medication adjustment in patients with renal impairment was 
reported to be 73.5% reported by Sweileh et al [11], the sample size was calculated using allowable error 
(d) in estimating a prevalence of 10%.  
 
The following formula was used for calculating the adequate sample size in prevalence study [20]; N=(Z 
α/2 2 pq)/d2 
 
Where N is the sample size, Z is the statistic corresponding to level of confidence, p is expected 
prevalence, and d is precision (corresponding to effect size) [20-22]. 
 
Based on a prevalence 73.5% and allowable error in estimating a prevalence of 10% where: 
p = 0.735 
q = 1-p = 0.265 
d = allowable error = 10% of p= 0.1*0.735=0.0735  
= probability of type I error  
= 0.05 (2-sided) = Z α/2 = Z 0.025=1.96 
N = ((1.96)2(0.735) (0.265))/(0.0735)2= 138.50 ≈ 139.  
 
Consequently, the minimum required sample size was 139 patients. Given the duration of the study, we 
ended up with 184 patients in the final analysis as shown below. 
  
During the study period, a total of 856 patients were admitted in the medical wards, 50.1% (n=429) males 
and 49.9% (n=427) females. Of these patients, 6% (n=52) had no record of renal functions from 
admission on the Integrated Patient Management System (IPMS). From the remaining 804 patients, 29% 
(n=233) had renal impairment, either on admission or they developed it during their hospital stay.  Of the 
233 patients with renal impairment, 49 were excluded from the final analysis due to either their folders not 
being traced, discharged/died within 24 hours, or they were admitted as lodgers. Hence, 184 patients 
were included in the final analysis, 54.3% (n=100) males and 45.7% (n= 84) females (Figure 1), higher 
than our sample size calculation. 
 
Insert Figure 1 
 
2.4 DATA COLLECTION 
The hospital Integrated Patient Management System (IPMS) was used to retrieve the total admissions 
into the male and female medical wards of Princess Marina Hospital from August to October 2016. The 
electronic medical record system (Meditech©) of each patient was searched using the unique patient 
number on admission assigned to each patient (PA number). The information retrieved was entered into 
an excel sheet. The following information was retrieved from the Electronic Medical Record (EMR) and 
folders of each patient: age, gender, serum creatinine on admission and their highest serum creatinine 
level while admitted which on computation resulted in the eGFR meeting the study definition of renal 
impairment described below. These variables were subsequently entered into an electronic calculator for 
Modification of Diet in Renal Disease (MDRD) approved by NKF-KDQOI clinical practice guidelines to 
obtain the estimated glomerular filtration rate (eGFR) [23]. The documented HIV serostatus of the 
patients were also retrieved from either the EMR or patient folders. The uptake of HIV testing is typically 
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high in the hospital as patients with unknown HIV status usually consent to be tested at the time of 
admission. 
 
The definition and classification of renal impairment differs among different information sources [5]. 
However, drug dosing guidelines are typically derived from studies performed in patients with stable, 
chronic renal insufficiency and the recommendations are extrapolated to seriously ill patients with acutely 
decreased renal function [24]. For the purpose of this study to evaluate appropriateness of drug dosing 
adjustment, renal impairment was defined as estimated GFR corresponding with CKD 3 or worse (<60 
mL/min/1.73 m2) [25]. The Charlson comorbidity index (CCI) was used to assess risk for both the 
inappropriateness of medication adjustment as well as outcome at discharge. CCI for each individual 
patient was computed using an online calculator [26]. For the purpose of this study, CCI was categorized 
as low (0-1), intermediate (2-3), high (4-5) and very high (≥6) similar to other studies [27, 28].  
 
Patients with eGFR values of <60 mL/min/1.73m2 had their medical records folders retrieved from the 
medical records department.  For all patients, detailed clinical data was collected using a structured Excel 
data sheet. Medications administered and dosage adjustments were recorded from day 2 of admission, or 
the date from which the first renal function test results were available, or from the date renal impairment 
developed in the scenario a patient was admitted with normal renal function and subsequently developed 
renal impairment during their hospital stay. For those patients identified with renal impairment, an audit 
was performed to assess if dosages of medications administered were adjusted appropriately according 
to standard formulae. Medication dosages recorded were correlated for dosages recommended 
according to their eGFR using Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and 
Children 5th edition [24]. This source was preferred because it has a section for medication adjustment in 
patients on continuous renal replacement therapy (CRRT) which was the case for some patients in this 
study. To ensure validity of findings of appropriateness of medications adjustment, data was checked and 
verified by two reviewers (the first two authors). 
 
Polypharmacy has a range of definitions that refer to different medication regimens without any standard 
definition [29]. For the purpose of this study, polypharmacy is defined as prescription containing four or 
more medications [30].  
 
2.5 MEDICATION WORK FLOW IN THE HOSPITAL 
For the purpose of this study, medications used for assessing the appropriateness of adjustments were 
those administered as appearing in the patients’ treatment charts. Medication work flow in the hospital 
begins with doctors prescribing medications and writing them in patients’ treatment charts. The majority of 
prescribed medications are available in the ward; consequently, nurses administer these as prescribed by 
the doctors. Pharmacists are not involved during the ward rounds to verify whether the medications have 
been appropriately adjusted in patients with comorbid conditions such as renal impairment or hepatic 
failure. Pharmacists can be involved whenever drugs listed as a special order category are prescribed 
and the files sent to Pharmacy for medication issuing. 
 
2.6 DATA MANAGEMENT AND STATISTICAL ANALYSIS 
Statistical Package for Social Sciences (SPSS) version 24.0 was used for analysis. Descriptive statistics 
was performed for social-demographic parameters and clinical characteristics and expressed in 
frequencies and percentages for categorical variables. For numerical variables, the median with 
interquartile range (IQR) and the mean (SD) were used as appropriate. Bivariate and multivariate logistic 
regression analyses were used to assess which patient factors were associated with inappropriate 
dosage adjustment. Due to the problem of collinearity, some variables were removed from multivariate 
model. A p-value of < 0.05 was considered statistically significant. 
 
2.7 ETHICAL CLEARANCE 
Ethical clearance to conduct this study was obtained from University of Botswana Office of Research and 
Development, Ministry of Health, Research and Development Division, and the Princess Marina Hospital 
Research and Ethics Committee. 
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Overall, we followed the STROBE checklist in the design and reporting of our findings 
(https://www.strobe-statement.org/fileadmin/Strobe/uploads/checklists/STROBE_checklist_v4_cross-
sectional.pdf). 
 
3. RESULTS 
 
3.1 Sociodemographic and clinical characteristics of study participants 
Table 1 describes the background and clinical characteristics of the patients enrolled in this study. The 
median age of patients was 53.0 years with an interquartile range (IQR) of 25-75 years. Male patients 
accounted for 54.3% of the patients. In terms of comorbidities, 71.2% (n=131) had comorbid conditions 
such as hypertension, diabetes and congestive cardiac failure. Hypertension and diabetes mellitus were 
present in 92/184 (50.0%) and 43/184 (23.4%) respectively. The HIV status was unknown in 14.7% 
(n=27), with 38.0% (n=70) being HIV negative and 47.3% (n=87) being HIV positive. On the other hand, 
among the enrolled patients, 33/184 (17.9%) were known to have end stage renal disease (ESRD) on 
continuous renal replacement therapy (CRRT). 
 
Insert Table 1 
 
The mean creatinine in mol/L was 462.8 with a range of 45-2702. Using the MDRD Study equation the 
mean eGFR ± SD was 29.3 mL/min/1.73m2 ± 24.7 mL/min/1.73m2. When patients were classified 
according to the corresponding KDIGO classification for CKD, 96.2% (n=177) of the patients had renal 
impairment stage III or worse (Table 1). Seven (7) patients were admitted with eGFR of >60 
mL/min/1.73m2 but developed renal impairment during the course of admission. 
 
Of the 184 patients, 61.9% (n=112) were prescribed at least one medicine that required dosage 
adjustment for the level of renal impairment. The median number of medications prescribed to patients 
with renal impairment was 6 (range= 0-13). The median (range) of the number of medicines than needed 
dosage adjustment was 1 (range= 0-6).  The overall mortality rate or patients admitted with renal 
impairment was 23.9% (n=44); whereas HIV positive patients with renal impairment had a mortality of 
28.7%, 
 
3.2 Appropriateness of dosage adjustment in renal impaired patients 
For the 184 patients with renal impairment there were 1143 prescription entries, of which 20.5% (n=234) 
required dosage adjustment for renal function. Out of the 234 entries, 54.3% (n= 127) were not 
appropriately dose adjusted. 
 
Among 112 patients that had prescriptions that needed dosage adjustment, 41.1% (n=46) of patients had 
none of their medications adjusted and only 30.4% (n=34) had all their medications appropriately 
adjusted. Over a quarter of patients, 28.6% (n=32), had some of their medications appropriately adjusted. 
 
3.3 Factors affecting dosage adjustment  
In the logistic regression model, gender, age of patient, history of diabetes mellitus, hypertension, 
comorbidities and severity of renal impairment had no association with medication dosing errors. The 
number of medicines needing renal adjustment that were prescribed did have a significant association. 
The higher the number of medicines prescribed, specifically 3 or more, the more likely that appropriate 
dosage adjustments would not be made (Adjusted OR= 13.78 (2.47, 76.74) p-value= 0.003) (Table 2).  
 
Insert Table 2 
 
3.4 Patients outcomes and associated factors  
Bivariate analysis was performed to assess if HIV status, comorbidities, extent of dosage adjustment, 
length of hospital stay and the degree of renal impairment have any association with the eventual 
outcome of either death or discharge of the 184 patients with renal impairment. All the variables except 
length of stay and the Charlson comorbidity index had no relationship with the eventual outcome. 
Mortality was noted to be significantly higher within the first 7 days of admission in patients with renal 
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impairment at 33.8% (25/74). Similarly, higher Charlson comorbidity index scores were significantly 
associated with mortality (Table 3).  
 
Insert Table 3 
 
Multivariate analysis revealed the following factors to be independently associated with a higher mortality 
rate;- high and very high Charlson comorbidity index and having part of the medications not adjusted. On 
the other hand, prolonged hospital stay of ≥15 days or more was associated with less likelihood of 
mortality among patients with renal impairment (Table 4) 
 
Insert Table 4 
 
3.5 Subgroup analysis of appropriateness of dosage adjustment among ESRD patients on dialysis 
Multivariate analysis involving 33 ESRD patients who were on dialysis revealed no association between 
studied variables (age, gender, HIV status, hospital stay duration, number of drugs needing dosage 
adjustment and Charlson comorbidity index score) and appropriateness of medication dosage adjustment 
(Table 5) 
 
Insert Table 5 
 
4. DISCUSSION 
 
This study found the prevalence of renal impairment among patients admitted in the medical wards at this 
leading hospital in Botswana at 29%, which was appreciably higher than previously reported in the same 
setting in 2014 where the prevalence of renal impairment was found to be 16.3% [31]. The possible 
explanation for this discrepancy in prevalence rates are differences in methodology with this being 
retrospective and including both patients with renal impairment on admission and those who developed 
renal impairment while admitted. This is in contrast to the previous study that only included patients with 
renal impairment at admission. In a regional study from South Africa conducted in Groote Schuur Hospital 
general medical wards, the authors found renal impairment in 32% of medical admissions [32]. However, 
an eGFR of <50 mL/min/1.73m2 was used in their study to define renal impairment compared to eGFR 
<60 mL/min/1.73m2 in this study. The prevalence of renal impairment amongst inpatients elsewhere in 
sub-Saharan Africa ranged from 9% to 55% [9, 33]. Consequently, our prevalence rate appears similar to 
those found elsewhere in sub-Saharan Africa. 
 
The mean age of patients admitted with renal impairment in this study was 54.6 years, which falls within 
the range of 42-63 years found in other similar studies [9, 11, 32]. The mean eGFR of the population 
group studied in our study was 29.3 ml/min/1.73 m2. This was almost identical to a study from Northern 
Ethiopia with a mean eGFR of 28.84 mL/min/1.73m2 [33]. However, in comparison to studies that used 
the Cockcroft Gault equation to calculate creatinine clearance (CrCl) it was much lower, with those 
studies finding mean CrCl ranging from 36-39.6 for their study populations [9, 11]. This difference could 
possibly be due to the different equations used [34]. In some studies, the MDRD study equation has been 
reported to be more accurate than the Cockcroft–Gault equation [35, 36], and has been shown to provide 
unbiased and reasonably accurate estimates across a wide range of subgroups when eGFR is less than 
60 ml/min per 1.73 m2 [37]. 
 
In this study, it was found that male patients seemed to be more prone to renal impairment than female 
patients though this was not statistically significant; with 55% of the total patients with renal impairment 
being male. This is in line with other published studies [9, 33, 38, 39]. This difference in susceptibility to 
renal impairment based on gender could be attributed to the fact that, on average, women have a lower 
muscle mass that may result in a lower serum creatinine and, thus, higher eGFR than men [40]. Whereas, 
it would have been plausible to compare body mass index (BMI) between male and female gender to 
verify this, this was not possible in this situation due to study design being retrospective and patients’ 
charts missing either weight or height information which are required for BMI calculations. 
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The median number of medicines prescribed to patients with renal impairment was six. The higher 
number of medications prescribed in our study may partly be explained by the fact that 68/112 (60.7%) of 
patients with medications required dosage adjustments were HIV positive; with an expected increased pill 
burden. Polypharmacy in patients with renal impairment has been found across many similar studies [9, 
32], and it is well established that the incidence of adverse drug events is much higher in patients with 
renal insufficiency [1, 2, 41]. 
 
Out of the 1143 prescription entries, 20.5% required dosage adjustment. This is similar to Decloedt et al 
who found 19% of the prescription entries requiring dosage adjustment [32]. However, the rates seen are 
half of those found in other studies where 39-42% of the prescriptions required dosage adjustment [33, 
42]. Our study also showed that 54.3% of the drug prescriptions were not appropriately adjusted. 
Comparing this to higher income countries, in an Australian hospital the dosages were found to be 
inappropriately high in 42.2 % of inpatients [43] and 34% of inpatients in a French Hospital [44]. In more 
resource limited settings, similar to ours, the findings are comparable with between 51 and 54.5% of 
medicines being inappropriately adjusted [9, 38]. 
 
When assessing patients’ factors that were associated with inappropriate dosage adjustment, we found 
that the higher the number of medicines prescribed, specifically 3 or more, the less likely that appropriate 
drug adjustments would be made. Severity of renal impairment was though not associated with increased 
likelihood of medication dosage errors.  Previous studies suggested predictors of medication dosing 
errors, i.e. severe-to-end stages of chronic kidney disease and/or renal impairment, the presence of 
comorbidities such as hypertension, and a higher number of prescribed medicines [39, 45]. We did not 
find a significant association between the presence of comorbidity and medication dosing errors. This 
finding is similar to a study conducted in Ethiopia [9].  
 
On the other hand, the mortality rate of patients admitted with renal impairment was 23.9%. The highest 
mortality rate was within the first 7 days of admission, i.e., 33.8%. This may be due to patients presenting 
very late with renal impairment, or presenting with illnesses with multisystem involvement. Even though it 
was not shown to be statistically significant, HIV positive patients with renal impairment had a mortality 
rate of 28.7%, which was higher than the overall mortality rate found in this study of 23.9%. This again 
may not be unsurprising, and will be the subject of future research projects. Patients with higher, very 
high Charlson comorbidity index and those with part of medications not adjusted were though significantly 
more likely to die, which agree with previous studies [46, 47]. 
 
Lastly, subgroup analysis involving patients on dialysis showed no significant association between 
medication adjustment errors and studied variables including age, gender, number of drugs requiring 
adjustment and Charlson comorbidity index scores. This contrast with previous findings which found 
higher rates of dosing errors among patients on dialysis [48, 49]. The possible reason for a lack of 
association in our study is that the sample size for this subgroup analysis was quite small and it may not 
have been powered to detect any association. We will be looking at this further in future studies. 
 
Study limitations 
Despite interesting findings elicited in this study, we are aware of several limitations with this study. 
Firstly, in the absence of a concise definition of renal impairment in the literature, we used an eGFR of 
<60 mL/min/1.73m2 which corresponds to CKD stage 3. Some studies have used this exact definition; 
however, we are aware of other studies that have used absolute serum creatinine values or lower cut offs 
of eGFR. Secondly, most dosing guidelines use stable GFR; some of patients in this study had AKI 
making their serum creatinine/GFR unstable. Consequently, there is a need for future studies to focus on 
dosing adjustment specifically for patients with stable GFR. Thirdly, prescriber factors, such as, level of 
training and years of experience were not captured, which could be a major confounder. We are also 
aware that we did not estimate the sample size; consequently, the relatively small sample size might have 
resulted in a lack of power to determine the association to some variables. However this being the first 
study on this topic in Botswana, we believe that our findings will motivate future studies with larger 
sample sizes to enhance more understanding and improve future care.  Furthermore, we used the MDRD 
equation to calculate GFR in this study. This equation has not been validated in this setting; likewise, this 
study is limited in the fact that we did not extract data on whether dosing adjustment was undertaken 
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using other equations such as CKD-EPI or Cockcroft-Gault equations although these tend to produce 
variable GFR estimations especially for CKD 2-3 and CKD 4-5. Lastly, this study was conducted 
retrospectively so as not to influence prescribing habits. Retrospective data collection may be hampered 
by missing and incomplete data, as in our study where 49 patients were excluded. Likewise, retrospective 
studies are bound to the problem of difficulties of estimating and measuring the effects of confounders. 
Never-the-less, we believe our findings are of interest which we will be taking further in future studies. 
 
5. Conclusions and recommendations 
We established that one in five prescriptions to patients with renal impairment in this leading hospital in 
Botswana required dosage adjustment, of which less than half were appropriately adjusted. The patient 
factor that we established in our setting to be related to inappropriate dosage adjustment was a higher 
number of prescribed medications. Higher scores of Charlson comorbidity index and hospital stay of 1 to 
7 days were independent predictors of mortality among patients with renal impairment. Continuous 
medical education and access to aides for clinicians to improve their prescribing needs to be emphasized. 
The collaboration of clinicians with pharmacy personnel is paramount in this regard with potentially Drugs 
and Therapeutic Committees playing an active educational role. We will be following this up in the future. 
 
We hope the findings of our study will be of interest to other African countries facing similar issues with 
high rates of both infectious and non-infectious diseases including patients with HIV as they struggle to 
manage patients effectively. 
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Figure 1: Flowchart of reviewed medical patients 
 
 
  
Admissions = 856 
 Males = 429 
 Females = 427 
Excluded = 52 (no creatinine 
on admission) 
Total admissions assessed = 804 
 Males = 405 
 Females = 399 
Excluded = 571  
(eGFR >60mL/min/1.73m2) 
Total admissions with renal impairment  
(eGFR <60mL/min/1.73m2) = 233 
 Males = 126 
 Females = 107 
Excluded = 49 
 Missing folders = 14 
 Discharged/died within 24 
hours = 35 
Included in final analysis = 184 
 Males = 100 
 Females = 84 
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Table 1: Background and clinical characteristics of patients who were either admitted with renal 
impairment or developed renal impairment during the course of admission (N=184) 
 
 Frequency Percentage 
Variables 
 
Gender 
Male 
Female 
 
100 
84 
 
54.3% 
45.7% 
Age in years; Median (IQR) 
14-29 
30-39 
40-49 
50-59 
60-69 
70 & above 
53 (25-75) 
14 
31 
36 
26 
36 
41 
 
7.6% 
16.8% 
19.6% 
14.1% 
19.6% 
22.3% 
Creatinine in umol/l; Mean (Range) 462.8 (45-2702)  
Estimated GFR (ml/min/1.73m2); Mean (SD) 
Stage 1 (≥ 90)* 
Stage 2 (60-89)* 
Stage 3 (30-59) 
Stage 4 (15-29) 
Stage 5 (< 15) 
29.3 (24.7) 
3 
4 
73 
41 
63 
 
1.6% 
2.2% 
39.7% 
22.3% 
34.2% 
Patients requiring at least one drug dose 
adjustment  
Yes 
No 
 
 
112 
72 
 
 
61.9% 
39.1% 
Number of medications prescribed; Median 
(Range) 
6 (0-13)  
No of drugs that need renal adjustment; 
Median (Range) 
 
1 (0-6) 
 
Comorbid conditions 
Yes 
No 
 
131 
53 
 
71.2% 
28.8% 
Diabetes 
Yes 
No 
 
43 
141 
 
23.4% 
76.6% 
Hypertension 
Yes 
No 
 
92 
92 
 
50% 
50% 
Charlson’s comorbidity index 
Low (0-1) 
Intermediate (2-3) 
High (4-5) 
Very high (≥6) 
 
9 
23 
28 
98 
 
5.7% 
14.6% 
17.7% 
62.0% 
HIV status 
Negative 
Positive 
Unknown 
 
70 
87 
27 
 
38.0% 
47.3% 
14.7% 
Number of medicines for HIV positive patients 
on antiretroviral therapy (mean) 
8.7  
Number of medicines for HIV positive patients 
not on antiretroviral therapy (mean) 
6.2  
*7 patients were admitted with normal renal functions but subsequently deteriorated over the course of hospital admission   
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Table 2: Factors associated with inappropriate dose adjustment in patients with renal impairment 
who needed dose adjustment (N=112) 
 
 Inappropriate
ly adjusted 
Appropriately 
adjusted 
Adjusted OR (95% 
CI) 
p-value 
Variables 
Gender 
Male 
Female 
 
42 (68.9%) 
36 (70.6%) 
 
19 (31.1%) 
15 (29.4%) 
 
Reference 
1.89(0.55, 6.34) 
 
0.31 
Age in years 
14-39 
40-49 
50-59 
60-69 
70 or more 
 
20 (74.1%) 
16 (64.0%) 
14 (70.0%) 
14 (66.7%) 
14 (73.7%) 
 
7 (25.9%) 
9 (36.0%) 
6 (30.0%) 
7 (33.3%) 
5 (26.3%) 
 
Reference 
0.59(0.13, 2.79) 
1.35(0.18, 10.03) 
1.69(0.23, 12.39) 
1.15(0.11, 12.40) 
 
 
0.51 
0.77 
0.60 
0.91 
HIV status 
Negative 
Positive 
Unknown 
 
20 (29.0%) 
53 (60.9%) 
5 (18.5%) 
 
49 (71.0%) 
34 (39.1%) 
22 (81.5%) 
 
Reference 
1.41(0.07, 28.49) 
 
 
0.82 
Hospital stay in days 
1-7 
8-14 
≥15 
 
24 (32.9%) 
26 (43.3%) 
28 (56.0%) 
 
49 (67.1%) 
34 (56.7%) 
22 (44.0%) 
 
Reference 
0.93(0.22, 4.01) 
0.47(0.11, 2.09) 
 
 
0.93 
0.32 
Comorbid conditions 
Yes  
No 
 
51 (68.9%) 
27 (71.1%) 
 
23 (31.1%) 
11 (28.9%) 
 
 
0.77(0.17, 3.47) 
Reference 
 
0.73 
Diabetes 
Yes 
No 
 
16 (37.2%) 
63 (44.7%) 
 
27 (62.8%) 
78 (55.3%) 
 
1.28(0.17, 9.60) 
Reference 
 
0.81 
Hypertension 
Yes 
No 
 
37 (40.2%) 
41 (45.1%) 
 
55 (59.8%) 
50 (54.9%) 
 
1.30(0.26, 6.62) 
 
0.75 
Charlson’s comorbidity index 
Low (0-1) 
Intermediate (2-3) 
High (4-5) 
Very high (≥6) 
 
0 (0.0%) 
7 (30.4%) 
9 (32.1%) 
57 (58.2%) 
 
8 (100.0%) 
16 (69.6%) 
19 (67.9%) 
41 (41.8%) 
 
- 
0.63(0.03, 13.82) 
1.02(0.07-14.88) 
Reference 
 
 
0.77 
0.99 
Number of drugs needing 
renal adjustment 
1 
2 
3 or more 
 
 
28 (54.9%) 
18 (66.7%) 
32 (94.1%) 
 
 
23 (45.1%) 
9 (33.3%) 
2 (5.9%) 
 
 
Reference 
1.34 (0.37, 4.83) 
13.78 (2.47, 76.74) 
 
 
 
0.65 
0.003 
Classification of renal 
impairment 
Stage 3 (eGFR 30-
59mL/min/1.73m2) 
Stage 4 (eGFR 15-
29mL/min/1.73m2) 
Stage 5 (eGFR 
<15mL/min/1.73m2) 
 
 
17 (56.7%) 
 
24 (75.0%) 
 
37 (74.0%) 
 
 
13 (43.3%) 
 
8 (25.0%) 
 
13 (26.0%) 
 
 
Reference 
 
1.22(0.26, 5.74) 
 
1.49(0.35, 6.46) 
 
 
 
 
0.80 
 
0.59 
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Table 3: Bivariate analysis of different factors versus outcome of admission for all patients with renal 
impairment 
        Variables Died Discharged p-value 
HIV status 
Negative 
Positive 
Unknown 
 
11 (6.0%) 
25 (13.6%) 
8 (4.3%) 
 
59 (32.1%) 
62 (33.7%) 
19 (10.3%) 
 
0.12 
Charlson’s comorbidity index 
Low (0-1) 
Intermediate (2-3) 
High (4-5) 
Very high (>5) 
 
0 (0%) 
1 (0.6%) 
8 (5.1%) 
28 (17.7%) 
 
9 (5.7%) 
22 (13.9%) 
20 (12.7%) 
70 (44.3) 
 
0.026 
Dosage adjustment 
None adjustable drugs appropriately adjusted 
Part of the adjustable drugs dose adjusted 
All adjustable drugs appropriately adjusted 
None of the drug needs adjustment of dose 
 
10 (5.4%) 
12 (6.5%) 
6 (3.3%) 
16 (8.7%) 
 
36 (19.6%) 
20 (10.9%) 
28 (15.2%) 
56 (30.4%) 
 
0.24 
Hospital stay in days 
1-7 
8-14 
≥15 
 
25 (13.6%) 
11 (6.0%) 
8 (4.3%) 
 
49 (26.6%) 
40 (21.7%) 
51 (27.7%) 
 
0.02 
Severity of renal impairment 
Stage 3 (eGFR 30-59mL/min/1.73m2) 
Stage 4 (eGFR 15-29mL/min/1.73m2) 
Stage 5 (eGFR <15mL/min/1.73m2) 
 
17 (9.2%) 
10 (5.4%) 
17 (9.2%) 
 
63 (32.1%) 
31 (17.4%) 
46 (26.6%) 
 
0.72 
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Table 4: Multivariate analysis of different factors versus death of patients with renal impairment 
 
        Variables Adjusted OR (95% 
CI) 
p-value 
HIV status 
Negative 
Positive 
Unknown 
 
Reference 
0.79 (0.17, 3.64) 
empty 
 
 
0.76 
 
Charlson’s comorbidity index 
Low-Intermediate(0-3) 
High(4-5) 
Very high(>6) 
 
Reference  
12.68(1.37,117.14)  
15.85(1.33, 188.78) 
 
 
0.025 
0.029 
Dosage adjustment 
None adjustable drugs appropriately adjusted 
Part of the adjustable drugs dose adjusted 
All adjustable drugs appropriately adjusted 
None of the drug needs adjustment of dose 
 
Reference 
3.42(1.06, 11.003) 
1.03 (0.25, 4.24) 
1.51 (0.46, 5.03) 
 
 
0.039 
0.97 
0.49 
Hospital stay in days 
1-7 
8-14 
≥15 
 
Reference 
0.41 (0.15, 1.11) 
 0.25 (0.09, 0.71) 
 
 
0.08 
0.009 
Severity of renal impairment 
Stage 3 (eGFR 30-59mL/min/1.73m2) 
Stage 4 (eGFR 15-29mL/min/1.73m2) 
Stage 5 (eGFR <15mL/min/1.73m2) 
 
Reference 
0.50 (0.15, 1.66) 
0.80(0.29-2.21) 
 
 
0.26 
0.67 
 
 
  
17 
 
Table 5: Subgroup analysis of factors associated with inappropriate dose adjustment among 
ESRD patients on dialysis (N=33)  
 
 Inappropriately 
adjusted 
Appropriately 
adjusted 
Adjusted OR 
(95% CI) 
p-value 
Variables 
Gender 
Male 
Female 
 
8 
8 
 
7 
10 
 
Reference 
1.05(0.05, 20.27) 
 
0.975 
Age in years 
14-49 
50 or more 
 
7 
9 
 
 
7 
10 
 
 
Reference 
0.83(0.02, 37.56) 
 
 
 
0.922 
HIV status 
Negative 
Positive 
Unknown 
 
6 
10 
0 
 
9 
6 
2 
 
 
Omitted* 
 
 
- 
Hospital stay in 
days 
1-7 
8-14 
≥15 
 
4 
6 
6 
 
6 
3 
8 
 
 
Omitted* 
 
 
- 
Comorbid 
conditions 
No 
Yes 
 
0 
16 
 
1 
16 
 
Omitted* 
 
          -  
Diabetes 
Yes 
No 
 
5 
11 
 
3 
14 
 
2.06(0.05, 83.52) 
Reference 
 
0.701 
Hypertension 
Yes 
No 
 
14 
2 
 
12 
5 
 
17.71(0.44, 
718.18) 
 
0.13 
Charlson’s 
comorbidity index 
Low-High(1-5) 
Very high(>5) 
 
4 
12 
 
 
9 
6 
 
 
Reference 
4.37(0.20, 94.76) 
 
 
 
0.35 
Number of drugs 
needing renal 
adjustment 
1 
2 
3 or more 
 
 
9 
3 
4 
 
 
3 
4 
1 
 
 
Reference 
0.08 (0.002, 2.83) 
0.22(0.002, 17.88) 
 
 
 
0.17 
0.50 
*Omitted due to collinearity 
 
